Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)

NCT07584031 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

ESCC

Interventions

DRUG: Combination therapy with chemotherapy and immunotherapy
OTHER: Surgery

Sponsor

Tianjin Medical University Cancer Institute and Hospital